NCT07439757 AI-Powered Precision Decision-Making for Pancreatic Diseases
| NCT ID | NCT07439757 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Changhai Hospital |
| Condition | Pancreatic Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2026-03-01 |
| Primary Completion | 2029-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2026-03-01 with a primary completion date of 2029-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This multicenter clinical trial evaluates an artificial intelligence (AI) system designed to assist in the diagnosis and management of pancreatic diseases. Using contrast-enhanced CT scans, the study compares the AI's recommendations against the decisions of experienced clinicians to verify the system's accuracy and safety in a real-world setting. Patients are categorized into three management groups: Intervention (surgery/treatment), Intensive Surveillance (close monitoring), or Routine Surveillance (standard follow-up). The primary goal is to determine if the AI system can reliably classify patients, reduce the risk of missing malignant lesions, and prevent unnecessary surgeries, thereby improving clinical decision-making for pancreatic conditions.
Eligibility Criteria
Inclusion Criteria: * Clinically suspected pancreatic disease. * Scheduled to undergo contrast-enhanced CT. * Signed informed consent form indicating agreement to participate. Exclusion Criteria: * History of pancreatic surgery. * Contraindications to contrast-enhanced CT, including known hypersensitivity to iodinated contrast media or severe renal/hepatic dysfunction. * Suboptimal image quality affecting diagnosis. * Concurrent participation in another interventional clinical trial. * Unsuitability for participation as determined by the investigator, including but not limited to: pregnancy or lactation, severe psychiatric disorders or cognitive impairment, significant comorbidities that may interfere with study results or patient safety.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07439757 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Pancreatic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07439757 currently recruiting?
Yes, NCT07439757 is actively recruiting participants. Contact the research team at lilly_wang@126.com for enrollment information.
Where is the NCT07439757 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07439757 clinical trial?
NCT07439757 is sponsored by Changhai Hospital. The trial plans to enroll 2,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.